{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T05:47:40Z","timestamp":1777528060637,"version":"3.51.4"},"reference-count":41,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"unspecified","delay-in-days":29,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000991","name":"Faculty of Medicine, Nursing and Health Sciences, Monash University","doi-asserted-by":"publisher","award":["Department of Nutrition, Dietetics & Food PhD Scho"],"award-info":[{"award-number":["Department of Nutrition, Dietetics & Food PhD Scho"]}],"id":[{"id":"10.13039\/501100000991","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Monash Health","award":["Allied Health 'Jump Start\u2019 Research Grant"],"award-info":[{"award-number":["Allied Health 'Jump Start\u2019 Research Grant"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,7,9]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cystic fibrosis (CF) is a genetic condition of impaired membrane electrolyte transport and is characterised by defects in the production and function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Ground-breaking CFTR modulator therapy has resulted in a notable shift in the clinical presentation and progressive nature of CF, across both pulmonary and extrapulmonary systems. Access to CFTR modulator therapies in people with CF is occurring in a staged, descending age process, with clinical trials focusing primarily on safety and efficacy. There is a lack of robust, real-world longitudinal data on CFTR modulator therapy in infants and young children where extrapulmonary outcomes such as growth, micronutrient status and pancreatic function are the key focus.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>Pancreatic, nutritional and clinical outcomes in children 0\u20135 years with CF during the first 2 years of CFTR modulator therapy (PaNC) is a prospective cohort study involving all eight tertiary paediatric CF centres in Australia. Infants and children 4 months to 5 years of age who are eligible for elexacaftor\/tezacaftor\/ivacaftor (ETI) or ivacaftor (IVA) meet the inclusion criteria for PaNC, with a total eligible cohort of 303 children at the commencement of recruitment. The primary outcomes are change in weight-for-length\/body mass index z score and change in serum micronutrient status, at 6\u201312 monthly intervals, during the first 2 years of treatment with ETI or IVA. Secondary outcomes include change in exocrine pancreatic function, measured by faecal elastase-1, change in the use and dose of pancreatic enzyme replacement therapy, nutritional and gastrointestinal therapies and change in sweat chloride levels. Linear mixed modelling will be used to analyse primary and secondary endpoints. This protocol is reported in accordance with \u2018The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement\u2019 reporting guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Overarching governance and ethics approval has been granted by Monash Health Human Research Ethics Committee, in addition to all eight sites receiving site-specific authorisation approvals prior to the commencement of recruitment. Opportunities for CF consumers to be involved in targeted dissemination plans will be initiated via CF Australia at the completion of the study period. Additionally, a summary of non-identifiable results will be provided to CF consumers and CF healthcare providers via scientific and lay conferences and via peer-reviewed journals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>ACTRN12624001185550; Pre-results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-097071","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T11:20:27Z","timestamp":1753874427000},"page":"e097071","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Pancreatic, nutritional and clinical outcomes in children 0\u20135 years with cystic fibrosis during the first 2 years of CFTR modulator therapy (PaNC): a multicentre prospective observational study protocol"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7393-7329","authenticated-orcid":false,"given":"Caitlin","family":"Miles","sequence":"first","affiliation":[{"name":"Nutrition and Dietetics, Monash Children\u2019s Hospital, Clayton, Victoria, Australia"},{"name":"Respiratory Medicine, Monash Children\u2019s Hospital, Clayton, Victoria, Australia"},{"name":"School of Clinical Sciences, Department of Nutrition, Dietetics and Food, Monash University, Clayton, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamarah","family":"Katz","sequence":"additional","affiliation":[{"name":"Nutrition and Dietetics, Sydney Children\u2019s Hospital, Randwick, New South Wales, Australia"},{"name":"School of Clinical Medicine, Discipline of Paediatrics and Child Health, UNSW Medicine & Health, Sydney, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jodi","family":"Grunert","sequence":"additional","affiliation":[{"name":"Nutrition Department, Women's and Children\u2019s Hospital, North Adelaide, South Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristyn","family":"Ford","sequence":"additional","affiliation":[{"name":"Nutrition and Dietetics, Royal Children\u2019s Hospital, Parkville, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4075-5681","authenticated-orcid":false,"given":"Carla","family":"Hall","sequence":"additional","affiliation":[{"name":"Nutrition and Dietetics, The Children\u2019s Hospital at Westmead, Westmead, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Hawthorn","sequence":"additional","affiliation":[{"name":"Nutrition and Dietetics, Queensland Children\u2019s Hospital, South Brisbane, Queensland, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise Wong","family":"See","sequence":"additional","affiliation":[{"name":"Nutrition and Dietetics, John Hunter Children\u2019s Hospital, Newcastle, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mylie","family":"McMahon","sequence":"additional","affiliation":[{"name":"Nutrition and Dietetics, Perth Children\u2019s Hospital, Nedlands, Western Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Vass","sequence":"additional","affiliation":[{"name":"Nutrition and Dietetics, Monash Children\u2019s Hospital, Clayton, Victoria, Australia"},{"name":"Respiratory Medicine, Monash Children\u2019s Hospital, Clayton, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Watkins","sequence":"additional","affiliation":[{"name":"Nutrition and Dietetics, Sydney Children\u2019s Hospital, Randwick, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gemma","family":"Zanardo","sequence":"additional","affiliation":[{"name":"Nutrition Department, Women's and Children\u2019s Hospital, North Adelaide, South Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabella","family":"Brookes","sequence":"additional","affiliation":[{"name":"Nutrition and Dietetics, Perth Children\u2019s Hospital, Nedlands, Perth, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siobhan","family":"Handley","sequence":"additional","affiliation":[{"name":"Nutrition and Dietetics, John Hunter Children\u2019s Hospital, Newcastle, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Talia","family":"Woodward","sequence":"additional","affiliation":[{"name":"Nutrition and Dietetics, Queensland Children\u2019s Hospital, South Brisbane, Queensland, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasmin","family":"Wademan","sequence":"additional","affiliation":[{"name":"Nutrition and Dietetics, Perth Children\u2019s Hospital, Nedlands, Perth, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bella","family":"Cameron","sequence":"additional","affiliation":[{"name":"Nutrition and Dietetics, Royal Children\u2019s Hospital, Parkville, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"King","sequence":"additional","affiliation":[{"name":"Nutrition and Dietetics, Royal Children\u2019s Hospital, Parkville, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gillian M","family":"Nixon","sequence":"additional","affiliation":[{"name":"Respiratory Medicine, Monash Children\u2019s Hospital, Clayton, Victoria, Australia"},{"name":"School of Clinical Sciences, Department of Paediatrics, Monash University, Clayton, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zoe","family":"Davidson","sequence":"additional","affiliation":[{"name":"School of Clinical Sciences, Department of Nutrition, Dietetics and Food, Monash University, Clayton, Victoria, Australia"},{"name":"School of Clinical Sciences, Department of Paediatrics, Monash University, Clayton, Victoria, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"2025121411351991000_15.7.e097071.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1300109"},{"key":"2025121411351991000_15.7.e097071.2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)00576-6"},{"key":"2025121411351991000_15.7.e097071.3","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/j.jcf.2017.06.011","article-title":"Pancreatic insufficiency in Cystic Fibrosis","volume":"16 Suppl 2","author":"Singh","year":"2017","journal-title":"J Cyst Fibros"},{"key":"2025121411351991000_15.7.e097071.4","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.914790","article-title":"The Exocrine Pancreas in Cystic Fibrosis in the Era of CFTR Modulation: A Mini Review","volume":"10","author":"McKay","year":"2022","journal-title":"Front Pediatr"},{"key":"2025121411351991000_15.7.e097071.5","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jcf.2022.08.008","article-title":"Cystic fibrosis transmembrane conductance regulator modulators and the exocrine pancreas: A scoping review","volume":"22","author":"Ramsey","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2025121411351991000_15.7.e097071.6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0174463","article-title":"Abdominal symptoms in cystic fibrosis and their relation to genotype, history, clinical and laboratory findings","volume":"12","author":"Tabori","year":"2017","journal-title":"PLoS One"},{"key":"2025121411351991000_15.7.e097071.7","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.jcf.2021.07.011","article-title":"Cystic Fibrosis Related Gastrointestinal Manifestations - Moving Forward","volume":"20","author":"Birimberg-Schwartz","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2025121411351991000_15.7.e097071.8","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jcf.2020.12.021","article-title":"Designing the GALAXY study: Partnering with the cystic fibrosis community to optimize assessment of gastrointestinal symptoms","volume":"20","author":"Freeman","year":"2021","journal-title":"J Cyst Fibros"},{"key":"2025121411351991000_15.7.e097071.9","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jcf.2022.10.006","article-title":"Multicenter prospective study showing a high gastrointestinal symptom burden in cystic fibrosis","volume":"22","author":"Moshiree","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2025121411351991000_15.7.e097071.10","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/MPG.0000000000003173","article-title":"Gastrointestinal Factors Associated With Hospitalization in Infants With Cystic Fibrosis: Results From the Baby Observational and Nutrition Study","volume":"73","author":"Sathe","year":"2021","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2025121411351991000_15.7.e097071.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01609-4"},{"key":"2025121411351991000_15.7.e097071.12","unstructured":"Cystic Fibrosis Foundation Patient Registry . Annual data report bethesda. Maryland Cystic Fibrosis Foundation; 2024."},{"key":"2025121411351991000_15.7.e097071.13","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.jand.2020.03.014","article-title":"Effect of CFTR Modulators on Anthropometric Parameters in Individuals with Cystic Fibrosis: An Evidence Analysis Center Systematic Review","volume":"121","author":"Bailey","year":"2021","journal-title":"J Acad Nutr Diet"},{"key":"2025121411351991000_15.7.e097071.14","first-page":"70","article-title":"Impact of highly effective modulator therapy on gastrointestinal symptoms and features in people with cystic fibrosis","volume":"54","author":"Cecchetti","year":"2025","journal-title":"Paediatr Respir Rev"},{"key":"2025121411351991000_15.7.e097071.15","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2017-210473"},{"key":"2025121411351991000_15.7.e097071.16","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2023-220100"},{"key":"2025121411351991000_15.7.e097071.17","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau7531","article-title":"In utero and postnatal VX-770 administration rescues multiorgan disease in a ferret model of cystic fibrosis","volume":"11","author":"Sun","year":"2019","journal-title":"Sci Transl Med"},{"key":"2025121411351991000_15.7.e097071.18","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1164\/rccm.202008-3177OC","article-title":"Ivacaftor in Infants Aged 4 to <12 Months with Cystic Fibrosis and a Gating Mutation. Results of a Two-Part Phase 3 Clinical Trial","volume":"203","author":"Davies","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2025121411351991000_15.7.e097071.19","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jcf.2024.03.012","article-title":"Safety and efficacy of ivacaftor in infants aged 1 to less than 4 months with cystic fibrosis","volume":"23","author":"McNally","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2025121411351991000_15.7.e097071.20","unstructured":"Buckingham RBAG . A Prospective Study to Evaluate Biological and Clinical Effects of Significantly Corrected CFTR Function in Infants and Young Children (BEGIN Study): NCT04509050. ClinicalTrials.gov: ClinicalTrial, 2020. Available: https:\/\/clinicaltrials.gov\/study\/NCT04509050?term=BEGIN&rank=4#study-overview"},{"key":"2025121411351991000_15.7.e097071.21","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-2600(15)00545-7","article-title":"Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study","volume":"4","author":"Davies","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2025121411351991000_15.7.e097071.22","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2213-2600(18)30202-9","article-title":"Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study","volume":"6","author":"Rosenfeld","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2025121411351991000_15.7.e097071.23","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jcf.2019.03.009","article-title":"An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5\u202fyears (KLIMB)","volume":"18","author":"Rosenfeld","year":"2019","journal-title":"J Cyst Fibros"},{"key":"2025121411351991000_15.7.e097071.24","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1164\/rccm.202301-0084OC","article-title":"Phase 3 Open-Label Clinical Trial of Elexacaftor\/Tezacaftor\/Ivacaftor in Children Aged 2-5 Years with Cystic Fibrosis and at Least One F508del Allele","volume":"208","author":"Goralski","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2025121411351991000_15.7.e097071.25","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202301-0021OC"},{"key":"2025121411351991000_15.7.e097071.26","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S2213-2600(16)30032-7","article-title":"Partial restoration of pancreatic function in a child with cystic fibrosis","volume":"4","author":"Howlett","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2025121411351991000_15.7.e097071.27","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-2522","article-title":"Growth in Prepubertal Children With Cystic Fibrosis Treated With Ivacaftor","volume":"139","author":"Stalvey","year":"2017","journal-title":"Pediatrics"},{"key":"2025121411351991000_15.7.e097071.28","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.arbr.2017.09.013","article-title":"Effects of Ivacaftor in Three Pediatric Siblings With Cystic Fibrosis Carrying the Mutations G551D And F508del","volume":"54","author":"Mainz","year":"2018","journal-title":"Arch Bronconeumol (Engl Ed)"},{"key":"2025121411351991000_15.7.e097071.29","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1002\/ppul.25065","article-title":"Persistent recovery of pancreatic function in patients with cystic fibrosis after ivacaftor","volume":"55","author":"Munce","year":"2020","journal-title":"Pediatr Pulmonol"},{"key":"2025121411351991000_15.7.e097071.30","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1513\/AnnalsATS.202006-614RL","article-title":"Appearance of Pancreatic Sufficiency and Discontinuation of Pancreatic Enzyme Replacement Therapy in Children with Cystic Fibrosis on Ivacaftor","volume":"18","author":"Hutchinson","year":"2021","journal-title":"Ann Am Thorac Soc"},{"key":"2025121411351991000_15.7.e097071.31","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1176815","article-title":"Real-life impact of highly effective CFTR modulator therapy in children with cystic fibrosis","volume":"14","author":"Olivier","year":"2023","journal-title":"Front Pharmacol"},{"key":"2025121411351991000_15.7.e097071.32","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.jcf.2023.09.005","article-title":"Changes in fecal elastase-1 following initiation of CFTR modulator therapy in pediatric patients with cystic fibrosis","volume":"22","author":"Stephenson","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2025121411351991000_15.7.e097071.33","doi-asserted-by":"crossref","first-page":"111124","DOI":"10.1016\/j.nut.2020.111124","article-title":"Body composition and weight changes after ivacaftor treatment in adults with cystic fibrosis carrying the G551 D cystic fibrosis transmembrane conductance regulator mutation: A double-blind, placebo-controlled, randomized, crossover study with open-label extension","volume":"85","author":"King","year":"2021","journal-title":"Nutrition"},{"key":"2025121411351991000_15.7.e097071.34","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jcf.2021.11.012","article-title":"Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis","volume":"21","author":"Petersen","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2025121411351991000_15.7.e097071.35","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/phar.2903","article-title":"Real world study on elexacaftor-tezacaftor-ivacaftor impact on cholesterol levels in adults with cystic fibrosis","volume":"44","author":"Lonabaugh","year":"2024","journal-title":"Pharmacotherapy"},{"key":"2025121411351991000_15.7.e097071.36","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jcf.2023.04.019","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on fat-soluble vitamin levels in children with cystic fibrosis","volume":"22","author":"Schembri","year":"2023","journal-title":"J Cyst Fibros"},{"key":"2025121411351991000_15.7.e097071.37","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/ppul.25781","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on vitamin D absorption in cystic fibrosis patients","volume":"57","author":"Wright","year":"2022","journal-title":"Pediatr Pulmonol"},{"key":"2025121411351991000_15.7.e097071.38","doi-asserted-by":"crossref","DOI":"10.1186\/s40348-024-00178-6","article-title":"Changes in vitamins and trace elements after initiation of highly effective CFTR modulator therapy in children and adults with cystic fibrosis - a real-life insight","volume":"11","author":"Fabricius","year":"2024","journal-title":"Mol Cell Pediatr"},{"key":"2025121411351991000_15.7.e097071.39","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1002\/ppul.26823","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor on lipid and fat-soluble vitamin levels and association with body mass index","volume":"59","author":"Patel","year":"2024","journal-title":"Pediatr Pulmonol"},{"key":"2025121411351991000_15.7.e097071.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2014.07.013"},{"key":"2025121411351991000_15.7.e097071.41","unstructured":"NHMRC . In: Australia Chf , ed. Statement on Consumer and Community involvement in Health and Medical Research. 1. NHMRC, 2016."}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-097071","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T19:35:33Z","timestamp":1765740933000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-097071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":41,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,30]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/bmjopen-2024-097071"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-097071","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}